ENRYLAZE

This brand name is authorized in Austria, Estonia, Finland, France, Croatia, Ireland, Italy, Lithuania

Active ingredients

The drug ENRYLAZE contains one active pharmaceutical ingredient (API):

1 Crisantaspase UNII D733ET3F9O - ASPARAGINASE ERWINIA CHRYSANTHEMI

Asparaginase hydrolyses asparagine to aspartic acid and ammonia. In contrast to normal cells, lymphoblastic tumour cells have a very limited capacity for synthesising asparagine because of a significantly reduced expression of asparagine synthetase. Therefore, they require asparagine which diffuses from the extracellular environment. As a result of asparaginase-induced asparagine depletion in serum, protein synthesis in lymphoblastic tumour cells is disturbed while sparing most normal cells. Read about Asparaginase

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ENRYLAZE Solution for injection/infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XX02	Asparaginase	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3046317
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 518830
Country: FR	Base de données publique des médicaments	Identifier(s): 67034579
Country: IT	Agenzia del Farmaco	Identifier(s): 050901014
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097797